E. Klouras, M. Elisaf
Abstract
After discovering proprotein convertase subtilisin/kexin type 9 (PCSK9) and its critical role in low density lipoprotein (LDL) receptor catabolism, more data concerning its function come to light. PCSK9 protein, which exhibits a close and complicated relation with the LDL receptor, appears to have a prominent role in lipoprotein metabolism, atherosclerosis and inflammation. Furthermore, a strong correlation of PCSK9 with cardiovascular risk factors is also observed, while PCSK9 seems to participate in various metabolic pathways. Finally, inhibition of PCSK9 can be an effective lipid lowering treatment.
Keywords: PCSK9 protein, monoclonal antibody, dyslipidemia